讲座人：Professor Richard B. Pearson
讲座题目：
Coordinated inhibition of ribosome synthesis and function provides a
novel and potent therapeutic approach to treat MYC driven malignancy.
单位：
Division of Research, Peter MacCallum Cancer Centre, and Sir Peter MacCallum
Department of Oncology, University of Melbourne, Australia
简介：
Professor Rick Pearson was appointed as the Head of the Cancer Signalling Laboratory at the Peter MacCallum
Cancer Centre in 1995 after 3 years as a Human Frontiers of Science Fellow at the Friedrich Miescher Institute in
Basel Switzerland. He is also CoHead of the Oncogenic Signalling and Growth Control Program at Peter Mac,
is an NHMRC Senior Research Fellow and Professorial Fellow in the Peter MacCallum Department of Oncology
at the University of Melbourne. A major focus of his research is to understand the molecular basis of the
regulation of cell growth and to use this knowledge to address how deregulation of cell growth contributes
to cancer. His laboratory has recently demonstrated that increases in a cell’s ability to make ribosomes,
the “machines” that make proteins, is absolutely required for the increased cell growth that is critical for
the development of cancers of the blood, ovary and skin. Importantly, they have shown that newly
identified inhibitors of ribosome production can be used to treat cancer opening the way to develop
new options for single agent and combination therapies for these cancers.
讲座人：Professor Ross Hannan
讲座题目：
Targeting the ribosome and RNA Polymerase I transcription to treat cancer;
a new paradigm for cancer therapeutics.
单位：
Centenary Chair of Cancer Research,
Head of Department, Cancer Biology and Therapeutics, John Curtin School of Medical Research,
ANU College of Medicine, Biology and Environment, Australian National University,
Canberra, Australia
简介：
Professor Ross Hannan is a Senior Fellow of the National Health and Medical Research Council of Australia,
and head of the Oncogenic Signaling and Growth Control Program in the Division of Research at the Peter
MacCallum Cancer Centre, Melbourne, Australia. He received his PhD from the University of Tasmania in
1994 before undertaking postdoctoral research in the USA. Since returning to Australia in 2000, he has held
prominent positions at the Baker Medical Research Institute and the Peter MacCallum Cancer Centre in
Melbourne. His research interests include; ribosome biogenesis, the genetic and epigenetic regulation
of ribosomal gene transcription during malignant transformation, nucleolar control of p53 function as
a target for cancer therapy and ribosomopathies. Most recently he has collaborated with the Pharmaceutical
industry to develop “first in class” small molecule inhibitors of RNA Polymerase I transcription for
the therapy of haematologicalcancers which are currently in phase 1 clinical trials. In April 2015 Professor
Hannan will take up a new position as the Centenary Chair of Cancer Research head the Department of
Cancer Biology and Therapeutics at the John Curtin School of Medical Research, Australian National University,
Canberra, Australia
讲座时间：5.14上午9时
讲座地点：6#309 会议室
讲座已录入教师培训系统，欢迎有兴趣参加的老师们提前预约，准时参加！
